Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Nima Aghdam, M.D.

Title
Institution
Department
Address
Phone

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Sholklapper T, Creswell M, Cantalino J, Markel M, Zwart A, Danner M, Ayoob M, Yung T, Collins B, Kumar D, Aghdam N, Rubin RS, Hankins R, Suy S, Collins S. Ejaculatory Function Following Stereotactic Body Radiation Therapy for Prostate Cancer. J Sex Med. 2022 Mar 16. PMID: 35305936.
    Citations:    Fields:    
  2. Pepin AN, Zwart A, Danner M, Ayoob M, Yung T, Collins BT, Kumar D, Suy S, Aghdam N, Collins SP. Treatment Interruptions During Stereotactic Body Radiotherapy for Prostate Cancer. Front Oncol. 2021; 11:796496. PMID: 35127506.
    Citations:    
  3. Aghdam N, Lischalk JW, Marin MP, Hall C, O'Connor T, Campbell L, Suy S, Collins SP, Margolis M, Krochmal R, Anderson E, Collins BT. Lobar Gross Endobronchial Disease Predicts for Overall Survival and Grade 5 Pulmonary Toxicity in Medically Inoperable Early Stage Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. Front Oncol. 2021; 11:728519. PMID: 34912703.
    Citations:    
  4. Ma TM, Roy S, Wu X, Mantz C, Fuller D, Miszczyk L, Napieralska A, Namysl-Kaletka A, Bagshaw HP, Buyyounouski MK, Glicksman R, Loblaw DA, Katz A, Upadhyaya SK, Nickols N, Steinberg ML, Philipson R, Aghdam N, Suy S, Pepin A, Collins SP, Boutros P, Rettig MB, Calais J, Wang M, Zaorsky N, Kishan AU. Refining the definition of biochemical failure in the era of stereotactic body radiation therapy for prostate cancer: The Phoenix definition and beyond. Radiother Oncol. 2022 Jan; 166:1-7. PMID: 34774650.
    Citations:    Fields:    
  5. Pepin A, Shah S, Pernia M, Lei S, Ayoob M, Danner M, Yung T, Collins BT, Suy S, Aghdam N, Collins SP. Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy. Front Oncol. 2021; 11:722852. PMID: 34604059.
    Citations:    
  6. Juarez JE, Romero T, Mantz CA, Pepin A, Aghdam N, Suy S, Steinberg ML, Levin-Epstein RG, Nickols NG, Kaplan ID, Meier RM, Pham HT, Linson PW, Hong RL, Buyyounouski MK, Bagshaw HP, Fuller DB, Katz AJ, Loblaw A, Collins SP, Kishan AU. Toxicity After Stereotactic Body Radiation Therapy for Prostate Cancer in Patients With Inflammatory Bowel Disease: A Multi-institutional Matched Case-Control Series. Adv Radiat Oncol. 2021 Nov-Dec; 6(6):100759. PMID: 34585025.
    Citations:    
  7. Pepin A, Pernia M, Danner MT, Ayoob M, Yung TM, Lei S, Collins BT, Simeng S, Aghdam N, Collins SP. Impact of Age on Patient-Reported Outcomes Following Stereotactic Body Radiation Therapy for Prostate Cancer. Cureus. 2021 Mar 09; 13(3):e13780. PMID: 33842156.
    Citations:    
  8. Aghdam N, Carrasquilla M, Wang E, Pepin AN, Danner M, Ayoob M, Yung T, Collins BT, Kumar D, Suy S, Collins SP, Lischalk JW. Ten-Year Single Institutional Analysis of Geographic and Demographic Characteristics of Patients Treated With Stereotactic Body Radiation Therapy for Localized Prostate Cancer. Front Oncol. 2020; 10:616286. PMID: 33718117.
    Citations:    
  9. van Dams R, Jiang NY, Fuller DB, Loblaw A, Jiang T, Katz AJ, Collins SP, Aghdam N, Suy S, Stephans KL, Yuan Y, Nickols NG, Murthy V, Telkhade TP, Kupelian PA, Steinberg ML, Romero T, Kishan AU. Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients. Int J Radiat Oncol Biol Phys. 2021 07 01; 110(3):731-737. PMID: 33493615.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  10. Carrasquilla M, Creswell ML, Pepin AN, Wang E, Forsthoefel M, McGunigal M, Bullock E, Lei S, Collins BT, Lischalk JW, Esposito G, Aghdam N, Kumar D, Suy S, Leger P, Hankins RA, Dawson NA, Collins SP. Rationale for Involved Field Stereotactic Body Radiation Therapy-Enhanced Intermittent Androgen Deprivation Therapy in Hormone-Sensitive Nodal Oligo-Recurrent Prostate Cancer Following Prostate Stereotactic Body Radiation Therapy. Front Oncol. 2020; 10:606260. PMID: 33537236.
    Citations:    
  11. Conroy D, Becht K, Forsthoefel M, Pepin AN, Lei S, Rashid A, Collins BT, Lischalk JW, Suy S, Aghdam N, Hankins RA, Collins SP. Utilization of Iodinated SpaceOAR Vue™ During Robotic Prostate Stereotactic Body Radiation Therapy (SBRT) to Identify the Rectal-Prostate Interface and Spare the Rectum: A Case Report. Front Oncol. 2020; 10:607698. PMID: 33489918.
    Citations: 1     
  12. Aghdam N, Repka MC, McGunigal M, Pepin A, Paydar I, Rudra S, Paudel N, Pernia Marin M, Suy S, Collins SP, Barnes W, Collins BT. Stereotactic Body Radiation Therapy: A Versatile, Well-Tolerated, and Effective Treatment Option for Extracranial Metastases From Primary Ovarian and Uterine Cancer. Front Oncol. 2020; 10:572564. PMID: 33425723.
    Citations:    
  13. Aghdam N, Pepin AN, Creswell M, Hsieh K, Smith C, Drescher N, Danner M, Ayoob M, Yung T, Lei S, Kumar D, Collins BT, Lischalk JW, Krishnan P, Suy S, Lynch J, Bandi G, Hankins RA, Collins SP. Management of Isolated Local Failures Following Stereotactic Body Radiation Therapy for Low to Intermediate Risk Prostate Cancer. Front Oncol. 2020; 10:551491. PMID: 33251131.
    Citations:    
  14. Levin-Epstein RG, Jiang NY, Wang X, Upadhyaya SK, Collins SP, Suy S, Aghdam N, Mantz C, Katz AJ, Miszczyk L, Napieralska A, Namysl-Kaletka A, Prionas N, Bagshaw H, Buyyounouski MK, Cao M, Agazaryan N, Dang A, Yuan Y, Kupelian PA, Zaorsky NG, Spratt DE, Mohamad O, Feng FY, Mahal BA, Boutros PC, Kishan AU, Juarez J, Shabsovich D, Jiang T, Kahlon S, Patel A, Patel J, Nickols NG, Steinberg ML, Fuller DB, Kishan AU. Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. Radiother Oncol. 2021 01; 154:207-213. PMID: 33035622.
    Citations: 4     Fields:    Translation:Humans
  15. Levin-Epstein R, Cook RR, Wong JK, Stock RG, Jeffrey Demanes D, Collins SP, Aghdam N, Suy S, Mantz C, Katz AJ, Nickols NG, Miszczyk L, Napieralska A, Namysl-Kaletka A, Prionas ND, Bagshaw H, Buyyounouski MK, Cao M, Mahal BA, Shabsovich D, Dang A, Yuan Y, Rettig MB, Chang AJ, Jackson WC, Spratt DE, Lehrer EJ, Zaorsky NG, Kupelian PA, Steinberg ML, Horwitz EM, Jiang NY, Kishan AU. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. Radiother Oncol. 2020 10; 151:26-32. PMID: 32663537.
    Citations: 8     Fields:    Translation:Humans
  16. Aghdam N, Pepin A, Buchberger D, Hirshberg J, Lei S, Ayoob M, Danner M, Yung T, Kumar D, Collins BT, Lynch J, Kataria S, Suy S, Collins SP. Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS = 15). Front Oncol. 2020; 10:1060. PMID: 32719744.
    Citations: 2     
  17. Aghdam N, McGunigal M, Wang H, Repka MC, Mete M, Fernandez S, Dash C, Al-Refaie WB, Unger KR. Ethnicity and insurance status predict metastatic disease presentation in prostate, breast, and non-small cell lung cancer. Cancer Med. 2020 08; 9(15):5362-5380. PMID: 32511873.
    Citations: 3     Fields:    Translation:Humans
  18. Pepin A, Aghdam N, Shah S, Kataria S, Tsou H, Datta S, Danner M, Ayoob M, Yung T, Lei S, Gurka M, Collins BT, Krishnan P, Suy S, Hankins R, Lynch JH, Collins SP. Urinary Morbidity in Men Treated With Stereotactic Body Radiation Therapy (SBRT) for Localized Prostate Cancer Following Transurethral Resection of the Prostate (TURP). Front Oncol. 2020; 10:555. PMID: 32432033.
    Citations: 1     
  19. Yoon S, Cao M, Aghdam N, Shabsovich D, Kahlon S, Ballas L, Collins S, Steinberg ML, Kishan AU. Prostate bed and organ-at-risk deformation: Prospective volumetric and dosimetric data from a phase II trial of stereotactic body radiotherapy after radical prostatectomy. Radiother Oncol. 2020 07; 148:44-50. PMID: 32311600.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  20. Aghdam N, Pepin A, Carrasquilla M, Johnson C, Danner M, Ayoob M, Yung T, Lei S, Collins BT, Kumar D, Suy S, Lynch J, Collins SP. Self-Reported Burden in Elderly Patients With Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT). Front Oncol. 2019; 9:1528. PMID: 32039015.
    Citations:    
  21. Jiang NY, Dang AT, Yuan Y, Chu FI, Shabsovich D, King CR, Collins SP, Aghdam N, Suy S, Mantz CA, Miszczyk L, Napieralska A, Namysl-Kaletka A, Bagshaw H, Prionas N, Buyyounouski MK, Jackson WC, Spratt DE, Nickols NG, Steinberg ML, Kupelian PA, Kishan AU. Multi-Institutional Analysis of Prostate-Specific Antigen Kinetics After Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2019 11 01; 105(3):628-636. PMID: 31276777.
    Citations: 9     Fields:    Translation:Humans
  22. Yuan Y, Aghdam N, King CR, Fuller DB, Weng J, Chu FI, Mardirossian G, Patel A, Nickols NG, Kupelian PA, Steinberg ML, Collins SP, Kishan AU. Testosterone Levels and Sexual Quality of Life After Stereotactic Body Radiation Therapy for Prostate Cancer: A Multi-Institutional Analysis of Prospective Trials. Int J Radiat Oncol Biol Phys. 2019 09 01; 105(1):149-154. PMID: 31108142.
    Citations: 2     Fields:    Translation:Humans
  23. Kishan AU, Dang A, Katz AJ, Mantz CA, Collins SP, Aghdam N, Chu FI, Kaplan ID, Appelbaum L, Fuller DB, Meier RM, Loblaw DA, Cheung P, Pham HT, Shaverdian N, Jiang N, Yuan Y, Bagshaw H, Prionas N, Buyyounouski MK, Spratt DE, Linson PW, Hong RL, Nickols NG, Steinberg ML, Kupelian PA, King CR. Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer. JAMA Netw Open. 2019 02 01; 2(2):e188006. PMID: 30735235.
    Citations: 61     Fields:    Translation:Humans
  24. Dess RT, Devasia TP, Aghdam N, Jackson WC, Soni PD, Smith CP, Mitchell AL, Suy S, Hamstra DA, Jolly S, Nguyen PL, Feng FY, Schipper MJ, Skolarus TA, Miller DC, Wittmann DA, Collins SP, Spratt DE. Patient-Reported Sexual Aid Utilization and Efficacy After Radiation Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018 06 01; 101(2):376-386. PMID: 29487023.
    Citations:    Fields:    Translation:Humans
  25. Repka MC, Aghdam N, Kataria SK, Campbell L, Suy S, Collins SP, Anderson E, Lischalk JW, Collins BT. Five-fraction SBRT for ultra-central NSCLC in-field recurrences following high-dose conventional radiation. Radiat Oncol. 2017 Oct 19; 12(1):162. PMID: 29052514.
    Citations: 3     Fields:    Translation:Humans
  26. Repka MC, Aghdam N, Karlin AW, Unger KR. Social determinants of stage IV anal cancer and the impact of pelvic radiotherapy in the metastatic setting. Cancer Med. 2017 Nov; 6(11):2497-2506. PMID: 28980407.
    Citations: 3     Fields:    Translation:Humans
  27. Dess RT, Hartman HE, Aghdam N, Jackson WC, Soni PD, Abugharib AE, Suy S, Desai NB, Zumsteg ZS, Mehra R, Morgan TM, Feng FY, Hamstra DA, Schipper MJ, Collins SP, Spratt DE. Erectile function after stereotactic body radiotherapy for localized prostate cancer. BJU Int. 2018 01; 121(1):61-68. PMID: 28710895.
    Citations: 5     Fields:    Translation:Humans
  28. Lischalk JW, Woo SM, Kataria S, Aghdam N, Paydar I, Repka MC, Anderson ED, Collins BT. Long-term outcomes of stereotactic body radiation therapy (SBRT) with fiducial tracking for inoperable stage I non-small cell lung cancer (NSCLC). J Radiat Oncol. 2016; 5(4):379-387. PMID: 28018523.
    Citations: 17     
  29. Menon SS, Uppal M, Randhawa S, Cheema MS, Aghdam N, Usala RL, Ghosh SP, Cheema AK, Dritschilo A. Radiation Metabolomics: Current Status and Future Directions. Front Oncol. 2016; 6:20. PMID: 26870697.
    Citations: 27     
  30. Spitz S, Felbaum D, Aghdam N, Sandhu F. Delayed postoperative C5 root palsy and the use of neurophysiologic monitoring. Eur Spine J. 2015 Dec; 24(12):2866-71. PMID: 26433583.
    Citations: 4     Fields:    Translation:Humans
  31. Mott BT, Eastman RT, Guha R, Sherlach KS, Siriwardana A, Shinn P, McKnight C, Michael S, Lacerda-Queiroz N, Patel PR, Khine P, Sun H, Kasbekar M, Aghdam N, Fontaine SD, Liu D, Mierzwa T, Mathews-Griner LA, Ferrer M, Renslo AR, Inglese J, Yuan J, Roepe PD, Su XZ, Thomas CJ. High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations. Sci Rep. 2015 Sep 25; 5:13891. PMID: 26403635.
    Citations: 49     Fields:    Translation:HumansAnimalsCells
  32. Di Carlo D, Aghdam N, Lee LP. Single-cell enzyme concentrations, kinetics, and inhibition analysis using high-density hydrodynamic cell isolation arrays. Anal Chem. 2006 Jul 15; 78(14):4925-30. PMID: 16841912.
    Citations: 79     Fields:    Translation:HumansCells
  33. Hung PJ, Lee PJ, Sabounchi P, Aghdam N, Lin R, Lee LP. A novel high aspect ratio microfluidic design to provide a stable and uniform microenvironment for cell growth in a high throughput mammalian cell culture array. Lab Chip. 2005 Jan; 5(1):44-8. PMID: 15616739.
    Citations: 43     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Aghdam's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (102)
Explore
_
Co-Authors (5)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.